Introduction
Prostate cancer is one of the most prevalent cancers worldwide and is the third leading cause of cancer-related death among men in Australia. 1 Imaging studies are critical in the evaluation of either initial cancer stage or when there is recurrence. Accurate initial staging is crucial as it has the greatest impact on prognostication and treatment planning. Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is expressed over 100-to 1000-fold in prostate cancer cell membranes compared to normal prostate cell membranes. 2, 3 This is further enhanced in patients with high-grade disease, metastatic disease and/or those who have progressed to advanced castrateresistant prostate cancer. 4 PSMA has been demonstrated within the prostate and in metastatic disease in lymph nodes, soft tissues and bone. Hence, it serves as an excellent biological target for molecular imaging assessment of patients with prostate cancer. 5 The current international guidelines including the National Comprehensive Cancer Network (NCCN), 6 European Association of Urology 7 and American Urological Associations 8 recommends computed tomography of the abdomen and pelvis (CT AP) or multiparametric magnetic resonance imaging (mp-MRI) and whole body bone scan (WBBS) as initial staging modalities of all newly diagnosed high-risk prostate cancer. These imaging modalities have shown only modest sensitivity and specificity in detecting early metastatic or oligometastatic disease with a reported sensitivity and specificity of 42% and 82% respectively for CT-detected nodal metastases. MRI also had poor performance, with similar specificity but only 39% sensitivity. 9 This is not surprising as the detection of nodal metastasis is based upon size criteria (usually larger than 8-10 mm) rather than functional information. It has been reported that about 80% of lymph node metastasis are less than 8 mm. 10 More recently, molecular imaging using 18 F-fluorodeoxyglucose, 11 C-choline or 11 C-acetate have shown promise in improving detection rates but these scans have been surpassed by the emergence of 68 Ga-prostate-specific membrane antigen ( 68 Ga-PSMA) PET scans. [11] [12] [13] [14] [15] [16] The use of 68 Ga-PSMA PET scans in the setting of biochemical recurrence is increasingly well-recognised, with reported sensitivities of up to 89.5% and detection rates of 42%, 58%, 76% and 95% for PSA categories <0.2, 0.2-1, 1-2 and >2 ng/mL respectively. 14, 17, 18 The use of 68 Ga-PSMA PET scans for initial staging of prostate cancer has been at the discretion of treating clinicians as this is not currently considered the standard of care. [6] [7] [8] Ga-PSMA on either a Phillips Gemini 4 CT scanner, Siemens Biograph or a Siemens MCT flow PET/CT camera. All studies were reported by fully accredited nuclear medicine specialists who had access to previous imaging results.
Staging classification
For the purposes of this study, the following classification system was derived which includes a separate category for oligometastatic disease.
• Stage A: Local disease confined to the prostate and seminal vesicles.
• Stage B: Regional nodes.
• Stage C: Oligometastatic disease (up to three distant metastases).
• Stage D: Widespread metastases.
Patients were staged post-conventional imaging and post-68 Ga-PSMA PET scans. Both stages were compared and analysed. Regional nodes were defined according to the 8th edition of the AJCC staging system as pelvic nodes below the bifurcation of the common iliac arteries and distant metastasis included lesions in non-regional nodes, bones and other sites. 19 Patients who were allocated Stage C and D disease post-conventional imaging were allocated based on two out of three conventional modalities of either CT AP, MRI or WBBS. If a suspicious lesion was found on only one imaging modality, these patients' initial staging was classified as inconclusive.
Results

A total of 131 patients who underwent
68 Ga-PSMA PET prior to definitive treatment were included in this study. Of 131 patients, 123 patients had an MRI, 99 patients had a WBBS and all patients had a CT AP as part of initial staging prior to 68 Ga-PSMA PET. Nine (7%) patients had non-PSMA avid primary of which four had high risk disease and the rest had intermediate risk disease. About 11 (8%) patients had suspicious bony lesions on a single modality and were classified as inconclusive initial stage based on conventional imaging.
Patient characteristics and clinical data for all patients (n = 131) are summarised in Table 1 . Median age was 70 years (range 49-84 years) and median initial PSA was 12 lg/mL (range 2.4-193 lg/mL). Gleason Score (GS) ranged between 6 and 10.
Based on the D'Amico risk stratification system, the majority of patients included in this study had high-risk prostate cancer. 20 Two main reasons that prompted 68 Ga-PSMA PET prior to definitive treatment include high-risk disease (n = 76) and suspicious lesions found on conventional imaging (n = 50).
Change in stage
According to the staging classification derived, the use of 68 Ga-PSMA PET in initial staging resulted in a change of stage in 37 (28%) patients. Seventeen (13%) patients were upstaged and twenty (15%) patients were downstaged. (see Table 2 )
Stage specific changes Table 3 by using the methodology for comparing margins in square contingency table provides P-value that is less than 0.001. 21 It is noteworthy that in the 11 (8%) patients with suspicious oligometastatic disease seen only on a single conventional imaging modality, all of them had oligometastatic disease excluded on 68 Ga-PSMA PET.
Probability of a change in stage based on conventional imaging 
Impact on management
Analysis on the impact of 68 Ga-PSMA PET on management was limited due to short follow-up period and management plans of some patients were not finalised when data collection concluded. Stage was changed in 37 patients and these patients were included in Table 4 Ga-PSMA PET. Seven out of eight patients who were upstaged from Stage A to B had definitive radiotherapy (RT), six with a boost to the PET positive node and one had definitive radiotherapy plus brachytherapy boost.
Four patients were upstaged from stage A to C. Two proceeded with radical RT with a plan for stereotactic ablative body radiotherapy (SABR) to oligometastatic disease.
Patients who were downstaged from B to A after 68 Ga-PSMA PET proceeded with definitive treatment with either RP or RT. Management plans were unlikely to have changed in these patients. Most patients (10 out of 12) who had oligometastatic disease excluded underwent definitive treatment with RP plus PLND and RT.
Use of conventional imaging
From our cohort of 131 patients, 32 (24%) patients did not have WBBS as part of initial staging. Of the 32 patients, 25 (19%) satisfied the criteria based on current international best practice guidelines for a WBBS of either PSA >20 or GS 8 or more or cT3-4 disease. [6] [7] [8] Another three patients satisfied the criteria based on NCCN of cT2 and PSA >10 for a WBBS. 6 This study also found that a total of 19 (19%) patients who had WBBS did not meet the criteria based on current international best practice guidelines for a WBBS. Eight (6%) patients did not have mp-MRI. One patient had MRI-incompatible metal implant and another patient was found to have widespread disease on CT AP and WBBS and MRI was not indicated. All patients who did not have mp-MRI had a CT AP.
Discussion
This study showed that approximately 20% of patients undergoing initial staging for prostate cancer in South Australia underwent 68 Ga-PSMA PET, even though that is not currently considered standard of care according to published guidelines. [6] [7] [8] For the purposes of this study, staging classification based on A, B, C and D was derived as it is thought that a change in stage based on this classification is likely to impact on management plans. This study found that the use of Ga-PSMA PET resulted in a change in stage in 21% of patients, of which only 2.8% of patients were downstaged. 23 Overall, management plans were altered in at least 24 (18%) patients. Most significantly, six patients with single regional LNM identified received dose escalation to PET-positive nodes. This could potentially translate into improved clinical outcomes. Two patients with oligometastatic disease received SABR. At least 10 (8%) patients with oligometastatic disease found on conventional imaging were excluded on 68 Ga-PSMA PET and subsequently underwent definitive treatment, although it is uncertain whether patients with oligometastatic disease would have otherwise not received definitive treatment. Another study by Sterzing et al. who investigated the use of 68 Ga-PSMA PET at initial staging and BCR showed that RT plans were modified in at least 50% of patients. 24 Analysis of LNM between conventional imaging and 68 Ga-PSMA PET in this study showed a discordance in 11% of patients. Possible explanations include small tumours below the resolution of PET, tumours located in areas of high physiological tracer uptake resulting in false-negative results or tumours with neuroendocrine differentiation. 14, 29 This study has a number of limitations. As this is a retrospective study, it is vulnerable to selection bias. The two most common reasons that 68 Ga-PSMA PET scans were performed were high-risk features and to exclude suspicious metastatic lesions seen on other imaging modalities. This may have accounted for the larger number of patients who were downstaged rather than upstaged. Furthermore, there was no pathological correlation to confirm the presence or absence of lymph nodes or metastatic disease as confirmed or excluded in the 68 Ga-PSMA PET scans. Follow-up outcome data are limited due to the short follow-up period for most of our patients and the results of a change in management remains to be evaluated. There was no accurate documentation of management plans based on stage prior to 68 Ga-PSMA PET. The impact on management of 68 Ga-PSMA PET was assessed based on the most likely management that would have been undertaken given the tumour stage prior to PSMA PET. Finally, it was particularly challenging to designate a stage post-conventional imaging when a suspicious lesion was found only on a single modality. We have classified them as inconclusive, but it is possible that more patients with oligometastatic disease were actually downstaged.
In conclusion, this retrospective analysis showed that the use of 68 Ga-PSMA PET scans in initial staging has a significant impact when compared to current recommended imaging modalities. The significant change in stage and management justifies its use in at least intermediate and high-risk disease. It is particularly useful when suspicious oligometastatic disease is found on conventional imaging modalities. Its utilisation in place of other conventional imaging such as WBBS remains an evidence-free area.
